Rezolute, Inc. - 8-K Filing

Rezolute achieves primary efficacy endpoint in Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events)

SEC EDGAR · November 13, 2026, 11:27 UTC

Tickers: $RZLT

Read the full article at SEC EDGAR

Part of the story Rezolute, Inc. - 4 Filing (3 articles)

More Regulatory news

Nova Minerals Corp - 8-K Filing SEC EDGAR · November 13, 2026, 11:45 UTC
Vertiv Holdings Co - 8-K Filing SEC EDGAR · November 13, 2026, 11:35 UTC
REGIONAL HEALTH PROPERTIES, INC - 10-Q Filing SEC EDGAR · November 13, 2026, 11:25 UTC
BLUE BIOFUELS, INC. - 10-Q Filing SEC EDGAR · November 13, 2026, 11:20 UTC
First Choice Healthcare Solutions, Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 11:19 UTC
OpenWorld, Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 11:04 UTC
NEKTAR THERAPEUTICS - 8-K Filing SEC EDGAR · November 13, 2026, 11:02 UTC
Weatherford International Corp - 8-K Filing SEC EDGAR · November 13, 2026, 11:04 UTC
iRhythm Holdings, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 11:00 UTC
King Resources Global, Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 11:06 UTC